Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean Follmann

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Nature Communications|March 23, 2023
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trialYouyi Fong, Yunda Huang, David Benkeser, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
NPJ Vaccines|May 3, 2026
Searching for immune correlates in Lassa vaccine development - workshop reportTrevor Brasel, Polina Brangel, Ifedayo Adetifa, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy TrialPeter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
The New England Journal of Medicine|November 24, 2020
A Randomized Trial of Convalescent Plasma in Covid-19 Severe PneumoniaVentura A Simonovich, Leandro D Burgos Pratx, Paula Scibona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Nature Communications|March 23, 2023
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trialYouyi Fong, Yunda Huang, David Benkeser, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
NPJ Vaccines|May 3, 2026
Searching for immune correlates in Lassa vaccine development - workshop reportTrevor Brasel, Polina Brangel, Ifedayo Adetifa, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy TrialPeter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
The New England Journal of Medicine|November 24, 2020
A Randomized Trial of Convalescent Plasma in Covid-19 Severe PneumoniaVentura A Simonovich, Leandro D Burgos Pratx, Paula Scibona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Pageof 15